Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DS-1594b |
Synonyms | |
Therapy Description |
DS-1594b is a menin inhibitor that blocks the interaction of menin with MLL (KMT2A), leading to decreased expression of target genes, potentially resulting in reduced cell proliferation of leukemic cells harboring MLL rearrangements (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DS-1594b | DS 1594b|DS1594b | MEN1-KMT2A Inhibitor 8 | DS-1594b is a menin inhibitor that blocks the interaction of menin with MLL (KMT2A), leading to decreased expression of target genes, potentially resulting in reduced cell proliferation of leukemic cells harboring MLL rearrangements (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04752163 | Phase Ib/II | Cyclophosphamide + Cytarabine + Dexamethasone + DS-1594b + Filgrastim + Mesna + Methotrexate + Vincristine Sulfate DS-1594b + Prednisone + Vincristine Sulfate DS-1594b Azacitidine + DS-1594b + Venetoclax Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate + Rituximab | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | Completed | USA | 0 |